Conversely, the activation score of TP53 pathway decreased from ICR1 to ICR4, in agreement with the higher rate of inactivating TP53 mutations reported in ICR4 previously reported in breast cancer [29]. This evidence concerns the gene TP53 and breast carcinoma.